ReviewFrontiers in microbiology2016
Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods.
Review in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03597841 (Turkish Prospective Cohort Study on Carbapenem Resistant Klebsiella Pneumonia Bacteremia), which is not on this map. Cited by 382 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Turkish Prospective Cohort Study on Carbapenem Resistant Klebsiella Pneumonia Bacteremia: a National Multicenter Observational Study
Who cites it
382 citing papers in PubMed, 2 syntheses or guidelines pooled it, 719 citations in OpenAlex.
- Prevalence of carbapenem-resistant gram-negative bacteria among neonates suspected for sepsis in Africa: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Prevalence and risk factors ofFrontiers in veterinary science · 2023Pooled it
- Dissemination ofEmerging microbes & infections · 2026Article
- Molecular Diagnostics for WHO Priority Bacterial Pathogens: A Bibliometric Mapping of Diagnostic Platforms, Resistance Markers, and Antimicrobial Resistance Research Trends.MicrobiologyOpen · 2026Review
- Prevalence, mortality, risk factors, and treatment of carbapenem-resistant hypervirulent Klebsiella pneumoniae: an evidence map.Infection · 2026Review
- Molecular Characterization and In Silico Functional Insights into Carbapenem Resistance in ClinicalPathogens (Basel, Switzerland) · 2026Article
- Genomic Epidemiology of Multidrug-Resistant Clinical Klebsiella pneumoniae From Pakistan.MicrobiologyOpen · 2026Article
- Frequency of Antimicrobial Resistance Among Fecal Bacteria Pathogens in an Informal Settlement in Nairobi, Kenya, 2018 to 2020.Microorganisms · 2026Article
- The genomic landscape of Klebsiella pneumoniae in Russia.World journal of microbiology & biotechnology · 2026Article
- Can Artificial Intelligence Transform Early Warning for Antimicrobial-Resistant Outbreak Clones? Approaches, Gaps, and Opportunities: A Scoping Review.Antibiotics (Basel, Switzerland) · 2026Review
- A One Health view of antimicrobial resistance in North Africa: Meta-analysis of ESBL-producing Enterobacteriaceae across sectors.One health (Amsterdam, Netherlands) · 2026Review
- Comprehensive Molecular Characterization of Extensively Drug-ResistantPharmaceuticals (Basel, Switzerland) · 2026Article
- Investigating the prevalence of KPC-2 and the variant KPC-144 in carbapenem-resistant Klebsiella pneumoniae and elucidating its molecular epidemiological and genetic characteristics.BMC microbiology · 2026Article
- Emergence and dissemination of extensively drug-resistant ST307Microbial genomics · 2026Article
- Detection of hypervirulence genes in carbapenem resistant Klebsiella pneumoniae from cancer patients at a tertiary referral hospital in Nepal.BMC infectious diseases · 2026Article
- Prevalence and Multidrug Resistance of WHO-Priority Bacterial Pathogens in a Romanian Intensive Care Unit.Journal of clinical medicine · 2026Article
- Genomic inference of sites of transmission during regional spread of blaNature communications · 2026Article
- Multicenter Analytical Performance Evaluation of the BD Phoenix NMIC-461 Panel for Carbapenemase Classification and Antimicrobial Susceptibility Testing ofAntibiotics (Basel, Switzerland) · 2026Article
- Under-diagnosed hypermucoviscousIJID regions · 2026Review
- Capsule Regulation ShapesInternational journal of molecular sciences · 2026Article
322 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of carbapenem-resistant Gram-negative pathogens poses a serious threat to public health worldwide. In particular, the increasing prevalence of carbapenem-resistant Klebsiella pneumoniae is a major source of concern. K. pneumoniae carbapenemases (KPCs) and carbapenemases of the oxacillinase-48 (OXA-48) type have been reported worldwide. New Delhi metallo-β-lactamase (NDM) carbapenemases were originally identified in Sweden in 2008 and have spread worldwide rapidly. In this review, we summarize the epidemiology of K. pneumoniae producing three carbapenemases (KPCs, NDMs, and OXA-48-like). Although the prevalence of each resistant strain varies geographically, K. pneumoniae producing KPCs, NDMs, and OXA-48-like carbapenemases have become rapidly disseminated. In addition, we used recently published molecular and genetic studies to analyze the mechanisms by which these three carbapenemases, and major K. pneumoniae clones, such as ST258 and ST11, have become globally prevalent. Because carbapenemase-producing K. pneumoniae are often resistant to most β-lactam antibiotics and many other non-β-lactam molecules, the therapeutic options available to treat infection with these strains are limited to colistin, polymyxin B, fosfomycin, tigecycline, and selected aminoglycosides. Although, combination therapy has been recommended for the treatment of severe carbapenemase-producing K. pneumoniae infections, the clinical evidence for this strategy is currently limited, and more accurate randomized controlled trials will be required to establish the most effective treatment regimen. Moreover, because rapid and accurate identification of the carbapenemase type found in K. pneumoniae may be difficult to achieve through phenotypic antibiotic susceptibility tests, novel molecular detection techniques are currently being developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.